Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening

J Inherit Metab Dis. 2010 Feb;33(1):43-50. doi: 10.1007/s10545-009-9003-z. Epub 2009 Dec 23.

Abstract

Background: Pompe disease is a rare, autosomal-recessive disorder which results from a defect in the lysosomal enzyme acid alpha-glucosidase (GAA). The onset of this disease is highly variable, with infantile types being the most severe. Traditionally, lymphocytes, fibroblasts or muscle biopsies were necessary for enzyme activity measurement, because these materials do not express maltase-glucoamylase (MGA) that interferes with the assay. Recently, acarbose was found to inhibit MGA activity selectively, so that dried blood became accessible for GAA assessment.

Aim: To evaluate the diagnostic efficacy of GAA measurement in dried blood specimens (DBSs) in comparison with lymphocytes. If DBSs provided reliable results, the diagnosis of Pompe disease could be facilitated, and high-throughput screening would become possible.

Methods and results: GAA activity was measured in DBSs of known patients at pH 3.8 (with and without acarbose) and at pH 7.0. Additionally, lymphocytes were obtained from the same patients, and the enzyme activity was determined at pH 4 to pH 7. In total, seven infantile patients and 29 patients with late-onset variants were investigated. All patients were reliably identified by both methods. Furthermore, a simplified protocol was established for neonatal screening.

Conclusion: The fluorometric technique for the assessment of GAA activity in DBS provides a reliable diagnosis for all variants of Pompe disease. The assay protocol could be simplified for neonatal screening, without increasing the false positive rate significantly or burdening the laboratory with time-consuming procedures.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biopsy
  • False Positive Reactions
  • Feasibility Studies
  • Fibroblasts / metabolism
  • Fluorometry / methods*
  • Glycogen Storage Disease Type II / blood*
  • Glycogen Storage Disease Type II / diagnosis*
  • Humans
  • Hydrogen-Ion Concentration
  • Infant, Newborn
  • Lymphocytes / metabolism*
  • Muscles / metabolism
  • Neonatal Screening / methods*
  • Reproducibility of Results
  • Time Factors
  • alpha-Glucosidases / metabolism

Substances

  • GAA protein, human
  • alpha-Glucosidases